シンポジウム7：免疫性神経疾患診療の最前線
多発性硬化症・視神経脊髄炎の分子標的治療
キーワード:
multiple sclerosis,
neuromyelitis optica,
monoclonal antibody,
disease modifying therapy,
clinical trial
2020 年 37 巻 3 号 p. 407-410
詳細
2020 年 37 巻 3 号 p. 407-410
Molecular targeted therapy including monoclonal antibody therapy is a new treatment strategy for demyelinating diseases such as multiple sclerosis (MS) and neuromyelitis optica (NMO). In Japan, only fingolimod and natalizumab are currently approved for treatment in MS. A novel S1P receptor modulator and a monoclonal antibody targeting CD20 are willing to be approved soon. In NMO, several monoclonal antibodies are waiting for the approval in Japan. Although either drug has a strong effect to prevent relapses in NMO, the indication should be considered by their high costs. In this review, I summarize the characteristics of each molecular targeted therapy.
